NCT00901849CompletedPhase 1
Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)
Roger Packer1 site in 1 country21 target enrollmentStarted: May 1, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Participants will remain on the trial for one year if benefiting from drug as demonstrated by radiographic evaluation and clinical evaluation.
Study Overview
Brief Summary
This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who have failed initial conventional treatment. In addition to evaluating the toxicity of this drug regimen, the potential efficacy of the regimen will be assessed.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- — to 21 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •children less than 21 years of age, with or without neurofibromatosis, with recurrent low-grade gliomas.
- •patients with or without NF1 must have failed some form of conventional therapy, radiotherapy, or chemotherapy (carboplatin/vincristine) to be eligible, including those treated wtih initial surgery. Patients do not have to have received radiotherapy to be eligible.
- •children with all types of histologically proven low-grade gliomas will be eligible; re-operation at the time of recurrence is not mandatory for entry on study.
- •patients with intrinsic brain lesions, believed neuroradiographically consistent with a low-grade glial tumor, with neurofibromatosis type 1 can be treated without histological confirmation.
- •patients without neurofibromatosis type 1 must have histological confirmation of a low-grade glial tumor prior to entry on study.
- •patients must have a Karnofsky score of greater than or equal to 50% for children greater than 10 years of age, or a Lansky score of greater than or equal to 50% for patients less than 10 years of age.
- •patients who are unable to walk because of paralysis, but who are able to use a wheelchair, will be considered ambulatory for purposes of assessing performance score.
- •patients must have a life expectancy of at least 12 weeks.
- •patients must be able to swallow medication in tablet form.
- •patients must have adequate organ function, including: peripheral ANC of greater than 1,000/microliters; a platelet count of greater than 100,000/microliters; hemoglobin of greater than 8 gms,dl (pRBC transfusions of allowed to maintain hemoglobin > 8 g/dl)
- •patients must have adequate renal function, which is defined as a normal serum creatinine for age
- •patients must have adequate liver function, as defined as a total bilirubin or less than 1.5 times the upper limit of normal for age, and an SGPT (ALT) of less than 2.5 times the upper limit of normal for age
- •patients must have had a MR scan within 3 weeks of starting treatment
- •all patients, and/or their parents or legal guardian, must sign a recent informed consent
- •all institutional, FDA, and NCI requirements for human study must be met.
Exclusion Criteria
- •patients must not have any other active tumors.
- •pregnancy or breast feeding is an exclusion criteria, as the potential mutagenicity and cytotoxicity of these drugs in developing fetuses are unknown. A pregnancy test must be obtained in females who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- •patients with uncontrolled infection are excluded.
- •patients who have previously received Tarceva or Rapamycin are excluded.
- •patients on antiepileptics and/or corticosteroids are allowed on study as long as they have been on a stable or weaning dose for 7 days prior to study initiation (defined as first day of treatment).
Outcomes
Primary Outcomes
Participants will remain on the trial for one year if benefiting from drug as demonstrated by radiographic evaluation and clinical evaluation.
Time Frame: one year
Secondary Outcomes
No secondary outcomes reported
Investigators
Roger Packer
Senior Vice President, Center for Neuroscience and Behavioral Medicine;
Children's National Research Institute
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell CarcinomaHead And Neck CancerNCT00942734M.D. Anderson Cancer Center49
Completed
Phase 2
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.Non-Small Cell Lung CancerNCT01998919Hoffmann-La Roche154
Completed
Phase 2
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)Lung CancerNon-Small Cell Lung CancerNCT00563784M.D. Anderson Cancer Center68
Recruiting
Phase 3
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis ComplexTuberous Sclerosis ComplexNCT05534672Katarzyna Kotulska200
Completed
Phase 2
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMASNonmalignant NeoplasmTuberous SclerosisLymphangioleimyomatosisKidney AngiomyolipomaNCT00126672Dana-Farber Cancer Institute36